Gilead Sciences: Seriously Undervalued At Peak Pessimism:
Gilead Sciences published financial results for the first quarter of 2024, which were better than I ...
seekingalpha.com/article/4696051-gilead-sciences-seriously-undervalued-at-peak-pessimism
Paid articlePaywallStory Details
| Last Updated | |
| Total Articles | 3 |
Main Topics
News on this topic
Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish: Gilead Sciences has an almost 5% dividend yield and overall, we can expect at least ...
seekingalpha.com/article/4695869-gilead-sciences-disappointing-fundamentals-and-sentiment-but-still-bullish
Paid articlePaywall Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows: Numerous drugs under development are projected to come to market later this year and next for ...
seekingalpha.com/article/4695781-unloved-gilead-due-for-reversal-on-flight-to-safety-money-flows
Paid articlePaywallSimilar to This
Previous
STAT 20h
Who will get the first psychedelic approved?: Today's biotech news examines Gilead's HIV prevention shot goes generic, Bright Minds' seizure drug ...
statnews.com/2026/11/03/biotech-news-who-will-get-the-first-psychedelic-approved/
Paid articlePaywall
The big winners of the tech wreck are biopharma stocks: The shares of large drugmakers like Lilly, Gilead and J&J keep hitting record highs.
trib.al/fkoKSQI
FDA approved Gilead's new once-daily HIV pill for patients on complex regimens: Bixlenvo combines two existing Gilead drugs into a single tablet for adults whose ...
qz.com/gilead-bixlenvo-fda-approval-hiv-pill-082826
Appeals court backs Gilead in ruling that threatens overseas prescription drug programs
qz.com/gilead-appeals-court-injunction-overseas-drug-imports-afps-081426
STAT Aug 03
California Supreme Court sides with Gilead in ‘duty’ to innovate case: Advocates argued Gilead was negligent for slow-walking development of an HIV medicine that ...
statnews.com/pharmalot/2026/08/03/california-supreme-court-sides-with-gilead-in-duty-to-innovate-case/
Paid articlePaywall
Africa: Open Letter to Gilead - Prevention Should Not Be a Privilege: MSF calls on Gilead for direct access to lenacapavir, as the current rollout falls far ...
allafrica.com/stories/202604020203.html
Bringing it home: SA is leading the charge to make anti-HIV jab for Africa : South Africa’s National Aids Council, Sanac, has asked local drug companies to ...
mg.co.za/health/2026-03-09-bringing-it-home-sa-is-leading-the-charge-to-make-anti-hiv-jab-for-africa/
The fight to make HIV ‘wonder drug’ affordable for Indians: Several Indian organisations are trying to block US firm Gilead’s patent claims ...
scroll.in/article/1090693/
Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA
finance.yahoo.com/news/gilead-sciences-inc-gild-kite-192657954.html
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year: Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong ...
seekingalpha.com/article/4734231-why-gilead-solid-q3-earnings-could-point-to-a-dividend-surprise-next-year
Paid articlePaywall Undercovered Dozen: EPR Properties, Gilead, Portland General Electric, CNH Industrial +
seekingalpha.com/article/4719568-undercovered-dozen-epr-properties-gilead-portland-general-electric-cnh-industrial-plus
Paid articlePaywall Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices: Gilead Sciences reported good quarterly results and in the last few weeks ...
seekingalpha.com/article/4718517-gilead-sciences-might-finally-be-on-its-way-to-higher-stock-prices
Paid articlePaywall Gilead Sciences: The Upcycle Is Just Getting Started: Learn why Gilead Sciences is a strong buy with promising growth potential in key drug franchises and an ...
seekingalpha.com/article/4706002-gilead-sciences-the-upcycle-is-just-getting-started
Paid articlePaywall Cassava Sciences: A 'Moon Shot' Becomes A Bigger 'Long Shot': Cassava Sciences, Inc., which has a late-stage candidate targeting Alzheimer's ...
seekingalpha.com/article/4702068-cassava-sciences-a-moon-shot-becomes-a-bigger-long-shot
Paid articlePaywall Gilead Sciences: Strategic Gains From Lenacapavir And Trodelvy Justify A Buy Rating
seekingalpha.com/article/4700693-gilead-sciences-strategic-gains-from-lenacapavir-and-trodelvy-justify-a-buy-rating
Paid articlePaywall Gilead Records Positive Phase III Results In HIV: Gilead Sciences' groundbreaking lenacapavir trial results could transform HIV prevention and treatment ...
seekingalpha.com/article/4700481-gilead-records-positive-phase-iii-results-in-hiv
Paid articlePaywall Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?: Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25 ...
seekingalpha.com/article/4685264-gilead-q1-earnings-preview-most-gains-wiped-out-cause-for-concern
Paid articlePaywall Gilead Sciences Finally Starts Succeeding: Gilead Sciences has new businesses and milestones planned for 2024. Click here to read the full investment analysis of ...
seekingalpha.com/article/4679557-gilead-sciences-finally-starts-succeeding
Paid articlePaywall Gilead Sciences: Cheap For A Reason: Gilead Sciences reported its Q4 2023 results, which paint a picture of a stagnant company. Read why GILD stock is a hold.
seekingalpha.com/article/4669249-gilead-sciences-cheap-for-a-reason
Paid articlePaywall Without A Clear Growth Path, Gilead Sciences Is A Hold: Gilead Sciences has seen stagnant sales growth over the past decade, but has potential for future growth ...
seekingalpha.com/article/4660512-without-a-clear-growth-path-gilead-sciences-stock-is-a-hold
Paid articlePaywall Next